-78%

est. 2Y upside i

HealthcareSeries A

Replacing orthodontic braces with our clear aligner and software

Rank

#3408

Sector

Healthcare, Dental Software, 3D Printing

Est. Liquidity

~4Y

Data Quality

Data: Medium

ArchForm operates in a growing market with a compelling value proposition (cost-effective in-office aligners) and FDA clearance, but faces a high incumbent threat from Align Technology and other established players.

Last updated: March 10, 2026

Bull (10%)+300%

ArchForm successfully leverages its cost-effective in-office 3D printing solution and proprietary software to capture significant market share from traditional aligner providers and other software competitors. Revenue accelerates to over $20M by 2028, attracting a Series B or C round at a $120M+ valuation, or an early acquisition by a strategic buyer looking to dominate the in-office aligner segment.

Base (45%)+50%

ArchForm continues its moderate growth trajectory, expanding its customer base among orthodontists seeking in-office aligner solutions, but faces persistent strong competition from dominant incumbents like Align Technology. Revenue grows steadily to ~$6M by 2028, leading to a modest Series B funding round at a $45M valuation, providing some return for early equity holders.

Bear (45%)-80%

ArchForm struggles to differentiate and scale against the extensive resources and market penetration of Align Technology and other well-funded competitors. Growth stalls, leading to challenges in securing further funding. The company either faces a down round, or is acquired for a low amount (e.g., $6M), significantly below the estimated current valuation, wiping out most common stock value given the $8M in liquidation preferences.

Est. time to liquidity~4.0 years

Preference Stack Risk

high

Investors hold $8M in liquidation preferences. In an exit at or below $8M, common stock holders would receive little to nothing. If the company exits at the estimated current valuation of $30M, common shareholders would share in the remaining $22M after preferences are paid.

Dilution Risk

high

As a Series A company, ArchForm will likely require additional funding rounds (Series B, C, etc.) before a liquidity event, which will lead to further dilution of existing equity.

Secondary Liquidity

none

There is currently no active secondary market or tender offers for ArchForm's equity, which is typical for a company at this stage.

Questions to Ask at the Interview

Strategic questions based on ArchForm's data — designed to show you've done your homework.

  • 1

    “Given Align Technology's dominance, what is ArchForm's precise strategy to capture significant market share, particularly in the next 2-3 years, and how do you plan to overcome their extensive network and R&D capabilities?”

  • 2

    “With current revenue around $4M and a Series A in 2020, what is the company's projected revenue growth rate for 2026 and 2027, and what are the key milestones ArchForm needs to hit to secure a successful Series B or C round?”

  • 3

    “Considering the Series A funding in 2020 and the typical timeline for venture-backed companies, how does ArchForm envision the path to a liquidity event for employees, and what is the company's philosophy on managing dilution in future funding rounds?”

Community

Valuation Sentiment

Our model estimates -78% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.